For other conditions, JAK-inhibitors have been used in a small number of patients with good outcomes, including STING-associated vasculopathy with onset in infancy, Aicardi-Goutières syndrome (AGS) and mutations interfering with IFN signaling (137). Here, IFNA1 is linked to Aicardi-Goutieres syndrome.